0001104659-19-040757.txt : 20190717
0001104659-19-040757.hdr.sgml : 20190717
20190717161434
ACCESSION NUMBER: 0001104659-19-040757
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190715
FILED AS OF DATE: 20190717
DATE AS OF CHANGE: 20190717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LANGER ROBERT
CENTRAL INDEX KEY: 0001239757
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38586
FILM NUMBER: 19959300
MAIL ADDRESS:
STREET 1: 98 MONTVALE RD
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rubius Therapeutics, Inc.
CENTRAL INDEX KEY: 0001709401
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042688109
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-679-9600
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
a4.xml
4
X0306
4
2019-07-15
0
0001709401
Rubius Therapeutics, Inc.
RUBY
0001239757
LANGER ROBERT
C/O RUBIUS THERAPEUTICS, INC.
399 BINNEY STREET, SUITE 300
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2019-07-15
4
M
0
7500
0.15
A
7500
D
Common Stock
2019-07-15
4
S
0
7500
14.9398
D
0
D
Stock Option (Right to Buy)
0.15
2019-07-15
4
M
0
7500
0
D
2025-02-04
Common Stock
7500
127500
D
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.70 to $15.42, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter.
/s/ Joanne M. Protano, Attorney-in-Fact
2019-07-17